WO2023135107 - PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
National phase entry:
Publication Number
WO/2023/135107
Publication Date
20.07.2023
International Application No.
PCT/EP2023/050382
International Filing Date
10.01.2023
Title **
[English]
PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
[French]
DÉRIVÉS PYRIDAZINYL AMINO UTILISÉS EN TANT QU'INHIBITEURS D'ALK5
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
PIZZIRANI, Daniela
c/o Chiesi Farmaceutici s.p.a.
Via Palermo 26/A
43122 Parma, IT
RONCHI, Paolo
c/o Chiesi Farmaceutici s.p.a.
Via Palermo 26/A
43122 Parma, IT
RESCIGNO, Donatella
c/o Chiesi Farmaceutici s.p.a.
Via Palermo 26/A
43122 Parma, IT
Priority Data
22150903.7
11.01.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1279 | |
| EPO | Filing, Examination | 5264 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 10419 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.[French]
La présente invention concerne un composé de formule générale (I) inhibant le récepteur de type I du facteur de croissance transformant β (TGF-β) (ALK5), des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles dans le traitement de maladies ou d'états associés à une dérégulation de la voie de signalisation ALK5 chez un mammifère.